Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.56 |
| ▸ | PDE4A | P27815 | 5/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808590 | 0.80 | PDE4B (0.55) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8189434 | 0.78 | MEN1 (0.67) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7423277 | 0.77 | PDE4D (0.78) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL21663533 | 0.77 | POLB (0.68) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2097509 | 0.76 | PDE4B (0.56) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL21851954 | 0.76 | NPSR1 (0.71) | POLBNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL29623507 | 0.75 | PDE4B (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL28450908 | 0.75 | PDE4B (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8197050 | 0.74 | PDE4D (0.82) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8748848 | 0.74 | PDE4D (0.67) | POLBPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-1429843-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | POLB 17/4885PDE4D 1307/4885PDE4A 1173/4885 |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | POLB 3020/4885PDE4D 9/4885PDE4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.